Adia Nutrition Inc. Identifies Over 20 Million Potentially Improperly Issued Shares and Initiates Process to Return Shares to Treasury
Adia Nutrition Inc. (OTCQB: ADIA) has discovered over 20 million potentially improperly issued shares during an internal audit of its historical share structure. The company has initiated legal proceedings to cancel these shares and return them to the treasury. The questionable shares were issued prior to current management and lack proper documentation and regulatory compliance.
CEO Larry Powalisz emphasized the company's commitment to corporate governance and shareholder value. While addressing these historical issues, Adia continues to focus on its core business of advancing stem cell therapies, including treatments for Multiple Sclerosis, orthopedic conditions, chronic pain, and wound repair.
Adia Nutrition Inc. (OTCQB: ADIA) ha scoperto, durante un audit interno sulla struttura azionaria storica, oltre 20 milioni di azioni potenzialmente emesse in modo improprio. La societ脿 ha avviato azioni legali per annullare queste azioni e reintegrarle nel portafoglio societario. Le azioni in questione sono state emesse prima dell'attuale management e risultano prive della documentazione e delle autorizzazioni regolamentari necessarie.
Il CEO Larry Powalisz ha sottolineato l'impegno dell'azienda verso una solida governance societaria e la tutela del valore per gli azionisti. Pur risolvendo queste questioni storiche, Adia continua a concentrarsi sul proprio core business, promuovendo terapie a base di cellule staminali per la Sclerosi Multipla, patologie ortopediche, dolore cronico e riparazione delle ferite.
Adia Nutrition Inc. (OTCQB: ADIA) descubri贸, durante una auditor铆a interna de su estructura accionaria hist贸rica, m谩s de 20 millones de acciones posiblemente emitidas de forma indebida. La compa帽铆a ha iniciado acciones legales para anular esas acciones y reincorporarlas al tesoro. Las acciones cuestionadas se emitieron antes del actual equipo directivo y carecen de la documentaci贸n y el cumplimiento normativo adecuados.
El CEO Larry Powalisz enfatiz贸 el compromiso de la empresa con la buena gobernanza corporativa y la protecci贸n del valor para los accionistas. Mientras se abordan estos asuntos hist贸ricos, Adia contin煤a enfocada en su negocio principal: desarrollar terapias con c茅lulas madre para la Esclerosis M煤ltiple, afecciones ortop茅dicas, dolor cr贸nico y reparaci贸n de heridas.
Adia Nutrition Inc. (OTCQB: ADIA)電� 瓿缄卑 欤检嫕 甑“鞐� 雽�頃� 雮措秬 臧愳偓鞐愳劀 鞎� 2觳滊 欤� 鞚挫儊鞚� 攵�鞝侅爤頃橁矊 氚滍枆霅� 臧�電レ劚鞚� 鞛堧姅 欤检嫕鞚� 氚滉铂頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 欤检嫕鞚� 旆唽頃橁碃 鞛愳偓欤茧 頇橃洂頃橁赴 鞙勴暣 氩曥爜 鞝堨皑毳� 鞁滌瀾頄堨姷雼堧嫟. 氍胳牅臧� 霅� 欤检嫕霌れ潃 順� 瓴届榿歆� 鞚挫爠鞐� 氚滍枆霅橃棃鞙茧┌ 鞝侅爤頃� 氍胳劀鞕� 攴滌牅 欷�靾橁皜 瓴办棳霅橃柎 鞛堨姷雼堧嫟.
CEO Larry Powalisz電� 旮办梾 瓯半矂雱岇姢鞕� 欤检＜ 臧�旃� 氤错樃鞐� 雽�頃� 須岇偓鞚� 鞚橃毳� 臧曥“頄堨姷雼堧嫟. 鞚措煬頃� 瓿缄卑 氍胳牅毳� 頃搓舶頃橂姅 霃欖晥鞐愲弰 Adia電� 雼る皽靹� 瓴巾檾歃�, 鞝曧槙鞕戈臣鞝� 歆堩櫂, 毵岇劚 韱奠 氚� 靸侅矘 旃橂毳� 韽暔頃� 欷勱赴靹疙彫 旃橂鞝� 臧滊皽鞚措澕電� 頃奠嫭 靷梾鞐� 瓿勳啀 歆戩頃橁碃 鞛堨姷雼堧嫟.
Adia Nutrition Inc. (OTCQB: ADIA) a d茅couvert, lors d'un audit interne de sa structure d'actions historique, plus de 20 millions d'actions potentiellement 茅mises de mani猫re incorrecte. La soci茅t茅 a engag茅 des proc茅dures judiciaires pour annuler ces actions et les restituer au portefeuille de l'entreprise. Les actions concern茅es ont 茅t茅 茅mises avant la direction actuelle et manquent de la documentation et de la conformit茅 r茅glementaire requises.
Le PDG Larry Powalisz a soulign茅 l'engagement de la soci茅t茅 en mati猫re de gouvernance d'entreprise et de protection de la valeur pour les actionnaires. Tout en traitant ces probl猫mes historiques, Adia continue de se concentrer sur son c艙ur de m茅tier : faire progresser les th茅rapies 脿 base de cellules souches, notamment pour la scl茅rose en plaques, les affections orthop茅diques, la douleur chronique et la r茅paration des plaies.
Adia Nutrition Inc. (OTCQB: ADIA) hat bei einer internen Pr眉fung der historischen Aktienstruktur 眉ber 20 Millionen potenziell fehlerhaft ausgegebene Aktien entdeckt. Das Unternehmen hat rechtliche Schritte eingeleitet, um diese Aktien aufzuheben und in den eigenen Bestand zur眉ckzuf眉hren. Die fraglichen Aktien wurden vor der aktuellen Gesch盲ftsleitung ausgegeben und weisen keine ordnungsgem盲脽e Dokumentation oder regulatorische Compliance auf.
CEO Larry Powalisz betonte das Bekenntnis des Unternehmens zu guter Unternehmensf眉hrung und zur Wahrung des Aktion盲rswerts. W盲hrend die historischen Angelegenheiten gekl盲rt werden, konzentriert sich Adia weiterhin auf sein Kerngesch盲ft: die Weiterentwicklung von Stammzelltherapien f眉r Multiple Sklerose, orthop盲dische Erkrankungen, chronische Schmerzen und Wundheilung.
- None.
- Discovery of potentially improper share issuances from previous management
- Legal proceedings could consume time and resources
- Historical documentation and regulatory compliance issues identified
Winter Park, Florida--(Newsfile Corp. - September 4, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company focused on advancing stem cell therapies for orthopedics, pain management, wound repair, and regenerative medicine, today announced that it has identified over 20 million shares that may have been improperly issued as part of an ongoing review of its historical share structure.
This discovery comes from a comprehensive internal audit designed to strengthen the integrity and transparency of the company's capitalization. The shares in question were issued before the current leadership took over and lacked proper documentation or regulatory compliance.
Adia Nutrition Inc. has confirmed with its legal counsel that they agree with the decision to address this matter and have filed the first case in the appropriate jurisdiction to seek the cancellation of these shares and their return to the company's treasury. This action is expected to strengthen the company's share structure without impacting ongoing operations or strategic initiatives.
"Our commitment to corporate governance and shareholder value remains paramount," said Larry Powalisz, CEO of Adia Nutrition Inc. "By proactively addressing these historical issues, we are taking decisive steps to rectify past discrepancies and position the company for sustained growth in the regenerative medicine sector."
The company will provide updates as the legal proceedings progress and continues to focus on its core mission of advancing stem cell therapies, including
Adia Nutrition will provide updates as the legal process moves forward and remains focused on its mission of advancing cutting-edge stem cell therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis, as well as treatments for orthopedic conditions, chronic pain, and complex wound repair.
For questions, inquiries, or additional information, please contact Larry Powalisz at [email protected] or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website:
Website:
Website:
Website:
Website:
Twitter (X):
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit
FAQ
How many potentially improper shares did Adia Nutrition (OTCQB: ADIA) identify?
What action is Adia Nutrition (ADIA) taking regarding the improper shares?
When were the questionable ADIA shares issued?
How will this share cancellation affect Adia Nutrition's operations?
What is Adia Nutrition's (ADIA) core business focus?
